0001746473-24-000012.txt : 20240124 0001746473-24-000012.hdr.sgml : 20240124 20240124165654 ACCESSION NUMBER: 0001746473-24-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240123 FILED AS OF DATE: 20240124 DATE AS OF CHANGE: 20240124 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Coulie Bernard CENTRAL INDEX KEY: 0001808895 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39303 FILM NUMBER: 24557197 MAIL ADDRESS: STREET 1: C/O PLIANT THERAPEUTICS, INC. STREET 2: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PLIANT THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001746473 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474272481 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-481-6770 MAIL ADDRESS: STREET 1: 260 LITTLEFIELD AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 wk-form4_1706133403.xml FORM 4 X0508 4 2024-01-23 0 0001746473 PLIANT THERAPEUTICS, INC. PLRX 0001808895 Coulie Bernard C/O PLIANT THERAPEUTICS, INC. 260 LITTLEFIELD AVENUE SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO 0 Common Stock 2024-01-23 4 A 0 128150 0 A 444532 D Common Stock 409317 I See footnote Stock Option (Right to Buy) 17.44 2024-01-23 4 A 0 256300 0 A 2034-01-23 Common Stock 256300 256300 D These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date. /s/Mike Ouimette, attorney-in-fact 2024-01-24